A Comparison of Recombinant Human Brain Natriuretic Peptide and Dobutamine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

104 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-01-31

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the therapeutic efficacy of recombinant human brain natriuretic peptide (rhBNP) with dobutamine on acute decompensated heart failure patients with different blood BNP levels

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Recombinant BNP on Heart and Renal Function in Acute Heart Failure

NCT01625403

Acute Heart Failure Acute Renal Failure

UNKNOWN PHASE2

Cardiac Hormone Replacement With Brain Natriuretic Peptide (BNP) in Heart Failure

NCT00252187

Congestive Heart Failure Cardiomyopathy

COMPLETED PHASE1/PHASE2

Preliminary Study on the Clinical Effect of Recombinant Human Brain Natriuretic Peptide on Sepsis Complicated With Heart Failure

NCT05111769

Sepsis

UNKNOWN NA

Effect of Recombinant Human Brain Natriuretic Peptide on Ventricular Remodeling and Cardiac Function in Patients With Acute Anterior Myocardial Infraction Undergoing Percutaneous Coronary Intervention

NCT06463808

Ventricular Remodeling Myocardial Infarction, Anterior Wall

RECRUITING

Early rhBNP on Myocardial Work in Patients With STEMI

NCT04157868

ST-Segment Elevated Myocardial Infarction

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with acute decompensated heart failure (ADHF) whose left ventricular ejection fraction(LVEF) was \<40%, were assigned to a high BNP group (BNP ≤ 3000 pg/mL) or an extra-high BNP group (BNP \> 3000 pg/mL) , depending on their admission plasma BNP levels. Each group was then subdivided into rhBNP or dobutamine subgroups according to intravenous administration with either rhBNP or dobutamine for 24-72h. The effects of rhBNP and dobutamine on patients in the high and extra-high BNP groups were compared.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Decompensated Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients were classified as NYHA class III-IV
* ejection fraction \<40%

Exclusion Criteria

* intravenous administration with rhBNP or dobutamine in the 2 weeks before study entry
* acute myocardial infarction
* significant valvular stenosis
* serious ventricular arrhythmia (frequent ventricular premature beat of \>5 bpm, nonsustained and sustained ventricular tachycardia)
* blood pressure \<95/60 mmHg or \>140/90 mmHg
* shock
* hypovolemia
* hepatic or renal impairment
* pregnant and lactating women.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No